Charpin C, Garcia S, Bergeret D, Andrac L, Horschowski N, Choux R, Lavaut M N
Department of Pathology, Faculté de Médecine Timore (IFR Immunologie et Cancérologie), Hôpital Nord, Marseille, France.
Br J Cancer. 1998 Jun;77(12):2274-80. doi: 10.1038/bjc.1998.378.
VLA2 is thought to be involved in the metastatic process in malignant tumours, in particular in carcinomatous cell adhesion to vessel basement membrane. VLA2 expression was immunohistochemically investigated in 204 breast carcinomas. Frozen tissue sections were probed with monoclonal anti-VLA2 using automated (Ventana ES 320 System) and quantitative (SAMBA 2005 image processor) immunoperoxidase. A positive anti-VLA2 immunoreaction was observed in 48 tumours (23.5%), within epithelial carcinomatous cells. The VLA2-positive surface in tumours varied from 3% to 20% (mean 8.75, S.D. 7.17) and was correlated with histoprognostic indicators and tumour expression of various antigens detected using the same method as that for VLA2. The results show that VLA2 immunoexpression was independent of the tumour size, grade, type and aneuploidy, and of the nodal status. VLA2 significantly correlated with ELAM, VCAM, VLA3 and P-glycoprotein (P-gp) (P < 0.01) and inversely correlated with cathepsin D (P < 0.001), but was independent of Ki67/MIB1, p53, bcl-2, c-erbB-2, E cadherin, CD44v, CD31, oestrogen and progesterone receptors' (ER, PR) antigenic sites and pS2. The exact role, if any, of VLA2 in tumour cell dissemination remains to be elucidated and the clinical relevance of VLA2 immunodetection in breast carcinomas requires further investigation of the correlation between VLA2 immunocytochemical expression and patients' outcome and response to chemotherapy.
人们认为VLA2参与恶性肿瘤的转移过程，尤其是癌细胞与血管基底膜的黏附。采用免疫组织化学方法对204例乳腺癌组织中的VLA2表达进行了研究。使用自动免疫过氧化物酶检测系统（Ventana ES 320系统）和定量免疫过氧化物酶检测系统（SAMBA 2005图像处理器），用抗VLA2单克隆抗体对冰冻组织切片进行检测。在48例肿瘤（23.5%）的上皮癌细胞中观察到抗VLA2免疫反应呈阳性。肿瘤中VLA2阳性表面面积在3%至20%之间（平均8.75，标准差7.17），并且与组织预后指标以及使用与检测VLA2相同的方法检测到的各种抗原的肿瘤表达相关。结果表明，VLA2免疫表达与肿瘤大小、分级、类型、非整倍体以及淋巴结状态无关。VLA2与ELAM、VCAM、VLA3和P糖蛋白（P-gp）显著相关（P < 0.01），与组织蛋白酶D呈负相关（P < 0.001），但与Ki67/MIB1、p53、bcl-2、c-erbB-2、E钙黏蛋白、CD44v、CD31、雌激素和孕激素受体（ER、PR）抗原位点以及pS2无关。VLA2在肿瘤细胞播散中的确切作用（如果有）仍有待阐明，VLA2免疫检测在乳腺癌中的临床相关性需要进一步研究VLA2免疫细胞化学表达与患者预后及化疗反应之间的相关性。
